Company: ForwardVue Pharma
Job title: Chief Executive Officer
Dr. Alan Franklin is Founder of ForwardVue Pharma. He has performed 40,000+ intravitreal injections as a practicing retina specialist with over 20 years of experience. Dr. Franklin has served as principle investigator in a number of diabetic retinopathy and AMD trials, presents his work internationally and published multiple manuscripts on candidate molecules to treat these diseases. He was recognized for best research by the Association of University Professors in Ophthalmology meeting for his work on a novel anti-angiogenic compound.
His other area of expertise is surgical visualization. Dr. Franklin is globally recognized for his publications and lectures on 3D Digitally Assisted Vitreoretinal Surgery and was recently awarded most watched video in 2019 by Retina Link Global for work on color channels. He also serves on several surgical visualization and development advisory boards.
Dr. Franklin completed his clinical training at University of Iowa Hospitals and Clinics for vitreoretinal diseases and surgery. While at University of Iowa, Dr. Franklin secured both HEED and HEED-Knapp scholarships. Prior to that, he did ophthalmology residency at Saint Louis University where he was chief resident in 1996-1997. He attended medical school at the Medical College of Ohio/University of Toledo. After graduating medical school, Dr. Franklin earned a PhD at Vanderbilt University in the Department of Molecular Physiology and Biophysics. His thesis focused upon the molecular biology and cell type specific gene expression in the insulin producing cells of the pancreatic islet. Dr. Franklin continued his training at Vanderbilt as a Medical Intern, and ultimately completed his thesis during internship and residency. As an undergraduate at Northwestern University he obtained a Bachelor of Science in Biomedical Engineering and earned a letter in Varsity Track.
Dr. Franklin is a member of the Academy of Ophthalmology, Association for Research in Vision and
Ophthalmology, American Society of Retina Specialists and the European Society of Retina Specialists
Chair-Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF 4:30 pm
day: Day One
ForwardVue Pharma: Long-Acting Therapeutics For Retinal Diseases 3:40 pm
• Working with Carboxyamidotriazole, CAI, which is a novel ORAI-1 blocker that diminishes intracellular calcium • CAI is a potent anti-angiogenic inhibitor based on multiple ocular and non-ocular pre-clinical models • CAI has an extensive human data safety set from clinical trials focused on advanced cancer • CAI also imparts neuroprotective effects in a rodent…Read more
day: Day One
Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics 10:45 am
Exploring extended-duration therapeutic possibilities with a focus on the anti-VEGF pathway Understanding how to increase drug durability and bring more convenient, safe drug delivery options to patients Achieving longer-term VEGF suppression through gene therapy, oral therapeutics or combination approaches with other drug modalitiesRead more
day: Day One